Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Inclusion Criteria: * Willing and able to provide written informed consent prior to any study-related procedures. * Patients should have an established diagnosis of IPF. * Pulmonary Function Tests (PFTs): FVC ≥ 50% and DLCO ≥ 25% of normal predicted values. * Able to walk at least 500 feet (150 meters) during the 6-minute Walk Test (6MWT). During the 6MWT the patient must not require greater than 51/min supplemental oxygen to maintain oxygen saturation \> 80% Exclusion Criteria: * Women who are pregnant or lactating; or who plan to become pregnant within 9 months after the infusion. * Women of childbearing potential or men who are considering fathering a child unless taking medically acceptable contraceptive precautions; * History of clinically significant environmental exposure, including dust, molds, asbestos, pigeons or other birds that may result in interstitial lung disease, or ingestion of a drug known to cause pulmonary fibrosis such as bleomycin. * History of clinically significant respiratory diseases other than IPF. * History of clinically significant cardiac, hepatic, or renal disease. * History of cancer, precancerous state (e.g. familial polyposis, BRCA1, BRCA2), other than non-melanomatous skin cancer, within 5 years prior to Screening. * Use of any investigational drug administered as part of a clinical trial within 12 weeks before Screening. * Other pathology that might interfere with the assessment of the safety or efficacy of the test article. * Other clinically significant, uncontrolled medical condition that, in the Investigator's opinion, might interfere with the assessment or follow-up.